Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399944 | 0.88 | ABL1 (0.58) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16363307 | 0.85 | JAK2 (0.55) | KDM4ERAB9ALMNAMAPTRXFP1 | |
| SCHEMBL19677819 | 0.85 | HAVCR2 (0.54) | KDM4EALDH1A1HSD17B10HPGDRAB9A | |
| SCHEMBL16363325 | 0.84 | HAVCR2 (0.49) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL16363337 | 0.79 | HAVCR2 (0.48) | KDM4ELMNAMAPTRXFP1HAVCR2 | |
| SCHEMBL16363316 | 0.78 | HSD17B10 (0.56) | KDM4EALDH1A1HSD17B10HPGDRAB9A | |
| SCHEMBL29073960 | 0.77 | — | — | |
| SCHEMBL16363306 | 0.76 | HAVCR2 (0.55) | KDM4EALDH1A1HSD17B10HPGDRAB9A | |
| SCHEMBL28674155 | 0.76 | JAK2 (0.44) | KDM4EALDH1A1HSD17B10RAB9ALMNA | |
| SCHEMBL16363323 | 0.75 | HAVCR2 (0.44) | KDM4ELMNAMAPTRXFP1HAVCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9670214-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | US | disclosed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | KDM4E 409/4885ALDH1A1 3382/4885HSD17B10 3611/4885 |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | KDM4E 740/4885ALDH1A1 2975/4885HSD17B10 2295/4885 |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | BCR, ABL1, ABL2 | KDM4E 729/4885ALDH1A1 1282/4885HSD17B10 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.